Wednesday, April 04, 2018 12:05:29 AM
Don't let emotions get the best of you.
Leading derms discuss the state of acne and the status of a potential new treatment from BioPharmX.
According to BioPharmX, it achieved the primary endpoint in its phase 2b clinical trial.
"These results represent a major milestone for the company and offer the potential of BPX-01 as the first topical gel minocycline for moderate-to-severe acne, optimizing safety and efficacy of a proven antibiotic for this condition to millions of patients," said Anja Krammer, co-founder and president of BioPharmX.
https://www.happi.com/contents/view_online-exclusives/2017-06-12/another-tool-for-treatment/
Leading derms discuss the state of acne and the status of a potential new treatment from BioPharmX.
According to BioPharmX, it achieved the primary endpoint in its phase 2b clinical trial.
"These results represent a major milestone for the company and offer the potential of BPX-01 as the first topical gel minocycline for moderate-to-severe acne, optimizing safety and efficacy of a proven antibiotic for this condition to millions of patients," said Anja Krammer, co-founder and president of BioPharmX.
https://www.happi.com/contents/view_online-exclusives/2017-06-12/another-tool-for-treatment/
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
